1231P - Clinical characteristics and real-world treatment patterns in stage I-III resectable NSCLC: THASSOS-INTL study

Background

The THASSOS-INTL (NCT04808050) evaluated the treatment (Tx) patterns and associated outcomes in patients (pts) with early-stage NSCLC from 7 countries in Asia-Pacific, and Middle East and Africa.

Methods

This multi-national, retrospective study enrolled adult pts (≥18 yrs) with resectable clinical stage (CS) IA-IIIB NSCLC diagnosed from 2013 to 2017, and followed until death, last recorded clinical visit, or 31 Dec 2020 (data cutoff). We present descriptive data on clinico demographics and Tx patterns (surgery [Sx], neoadjuvant therapy [NT], adjuvant therapy [AT], and NT+AT) of the overall cohort.

Results

Of 755 pts enrolled (CS I: 231 [30.6%], CS II: 264 [35.0%], CS III: 258 [34.2%]), median age was 62 [range: 56–69] yrs, 69.3% (523/755) were male, 75.0% (492/656) were current/former smokers, and 92.2% (436/473) had ECOG ≤1. Majority had adenocarcinoma (60.8% [434/714]), T1a–T2b tumors (65.9% [496/753]), right-lung involvement (58.9% [439/745]), and N0 status (55.6% [419/753]). Of 24.2% (183/755) pts tested for EGFR, 28.4% (52/183) were positive while 23 of 44 pts tested (52.3%) had PD-L1 expression (≥1%: 16; unknown: 7). Overall, 82.9% (626/755) had Sx of whom 39.1% (245/626) had Sx alone; 21.1% received NT, 51.1% received AT, and 5.8% received NT+AT (Table). In total, 58 pts received targeted therapy (AT: 47; NT:11), and 24 pts received immunotherapy (AT: 22; NT: 2). Of 43.8% (331/755) with disease progression, 68.3% (226/331) received systemic therapy (ST) and 50.2% (166/331) received radiotherapy (RT). Table: 1231P

Conclusions

This real-world study shows that ⁓39% of pts underwent Sx only, mostly in CS I, and ⁓70% received NT/AT, mostly in CS II and CS III. Biomarker testing at diagnosis was low with <25% tested for EGFR and <10% for PD-L1. With recent readouts of new NT and AT targeted and immunotherapies, multidisciplinary team management may improve biomarker testing rates and the use of novel agents in NT and/or AT settings for eligible pts to improve survival.

Clinical trial identification

NCT04808050.

Editorial acknowledgement

The authors would also like to thank Dr. Debasri Mukherjee and Dr. Soma Das of Fortrea Scientific Pvt Ltd for medical writing support that was funded by AstraZeneca International in accordance with Good Publication Practices 2022 guidelines.

Legal entity responsible for the study

AstraZeneca International.

Funding

AstraZeneca International.

Disclosure

K. Prabhash: Financial Interests, Institutional, Research Grant: Janssen, Aurigene, Roche. R. Moor: Financial Interests, Institutional, Other, Travel and meeting support: MSD, BMS, AstraZeneca, Roche, Novartis. F.J. Gonzalez Hernandez, E. Mohamed, P. Kantharaju, F. Sadek: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca. All other authors have declared no conflicts of interest.